**ACCESS TO CANCER MEDICINES IN THE ASIA-PACIFIC (APAC) REGION**

**APAC ACCOUNTS FOR 55% OF THE GLOBAL CANCER BURDEN**

<table>
<thead>
<tr>
<th>Country</th>
<th>No. of Cancer Patients</th>
<th>No. of Cancer Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global</td>
<td>14,067,894</td>
<td>8,202,000</td>
</tr>
<tr>
<td>China</td>
<td>3,065,438</td>
<td>2,205,946</td>
</tr>
<tr>
<td>India</td>
<td>1,014,934</td>
<td>682,830</td>
</tr>
<tr>
<td>Japan</td>
<td>703,863</td>
<td>378,636</td>
</tr>
<tr>
<td>Korea</td>
<td>219,520</td>
<td>81,510</td>
</tr>
<tr>
<td>Thailand</td>
<td>123,801</td>
<td>84,981</td>
</tr>
<tr>
<td>Australia</td>
<td>122,031</td>
<td>43,403</td>
</tr>
<tr>
<td>Malaysia</td>
<td>37,426</td>
<td>21,678</td>
</tr>
</tbody>
</table>

**SIGNIFICANT SCIENTIFIC ADVANCES ARE BEING MADE IN CANCER MEDICINE DEVELOPMENT**

Robust pharmaceutical research and development for new cancer products continues.

- **# of Pipeline Cancer Compounds Globally**
  - Phase II: 445
  - Phase III: 150

**MORE NEEDS TO BE DONE TO ENHANCE ACCESS TO CANCER MEDICINES**

The European Medicines Agency (EMA) approved 40 cancer medicines between 2009-2014, but only a portion is approved in APAC.

Average delay in approval relative to EMA (# of months)

- Canada: 4 months
- Australia: 8 months
- Korea: 8 months
- India: 12 months
- Malaysia: 12 months
- Japan: 17 months
- Taiwan: 18 months
- Thailand: 19 months

Note: China is excluded since very few products are approved.
Even fewer of these life-saving or life extending cancer medicines are reimbursed in APAC.

CONCLUSION

Barriers to cancer medicine access persist in APAC countries. In order to ensure patients have timely access to the latest life saving and life-extending innovations, governments in APAC need to:

- Increase investments in cancer prevention, diagnosis and treatment
- Develop more efficient regulatory pathways to ensure the “drug lag” in APAC is minimized
- Streamline reimbursement review processes to minimize the “patient access lag” to innovative oncology medicines
- Identify innovative pathways to fund cancer medicines in markets without reimbursement systems

* Data from IMS research (March 2016)